-
Sector Analysis
Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2035
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the obesity market through 2035. - In 2025, GlobalData estimated the total obesity market to be valued at $34.6 billion across the 7MM, with the US accounting for 82.6% of the market. Over the forecast period, the obesity market is anticipated to grow to a value of $118.2 billion in 2035. - There will be an increase in therapies with longer duration of action, such...
-
Sector Analysis
Overweight and Obesity: Epidemiology Report and Forecast to 2035
Why Does Overweight and Obesity Epidemiology Matter? Overweight and obesity are major health conditions associated with excess body fat, metabolic dysfunction, chronic inflammation, and comorbidities including diabetes and cardiovascular disease. Understanding the size and characteristics of these populations is essential for healthcare and life sciences companies developing products and commercial strategies. This report provides a comprehensive epidemiological assessment across the seven major markets (7MM), covering the US, France, Germany, Italy, Spain, the UK, and Japan. You can use this report...
-
Sector Analysis
Role of Compounding Pharmacies in Sating Appetite for GLP-1s
Against the backdrop of a global surge in demand for drugs based on the GLP-1 receptor agonists (GLP-1 RAs), semaglutide and tirzepatide, compounding pharmacies have come to the fore. This is not only for their traditional role of providing personalized dosing, but also because of their role in helping combat shortages and their ability to provide low-priced alternatives to originator brands. In some countries, this has led to increased scrutiny in terms of the quality of compounded versions, as well...
-
Sector Analysis
NHS England's Plans to Optimize Cost-Effectiveness of New Weight Loss Drugs, Including Phased 12-Year Model for Mounjaro
National Health Service (NHS) England has pioneered a novel 12-year trial scheme to help ensure cost-effective reimbursement of Eli Lilly's (US) innovative weight loss drug Mounjaro (tirzepatide) to NHS patients, by prioritizing those most in need and evaluating several possible provision models in parallel in patients with the greatest need before expanding to a broader population.
-
Sector Analysis
Obesity in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2031
This report covers the 68 geographical markets and provides an Excel-based forecast model for the obesity market through 2031. Across the 68 markets, sales in the obesity market were $12.3 billion in 2021, growing to $206.5 billion in 2031. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 85% and 84% of 68-market sales in 2021 and 2031, respectively.
-
Sector Analysis
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists in Type 2 Diabetes and Obesity Market Report Overview The GLP-1R agonists in the type 2 diabetes and obesity market size across the 68M was $39.2 billion in 2023. The GLP-1R agonists in the type 2 diabetes and obesity market will witness significant growth during the forecast period. GLP-1R Agonists in the Type 2 Diabetes and Obesity Market Outlook, 2023-2033 ($ Billion) Buy the Full Report to Know More about the GLP-1R Agonists in the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.